STERIS Reports 9.9% Revenue Growth to $1.46 Billion in Q2 Fiscal 2026

STERIS plc reported a significant increase in financial performance for the second quarter and first half of fiscal 2026, with total revenues reaching $1.46 billion for the three months ended September 30, 2025, a 9.9% increase from $1.33 billion in the same period last year. For the first six months, revenues rose 9.3% to $2.85 billion compared to $2.61 billion in the prior year. The growth was driven by higher volumes and pricing across all three business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The company’s net income attributable to shareholders for the second quarter was $191.9 million, up from $150 million a year earlier, while net income for the first half increased to $369.2 million from $295.4 million.

The company’s gross profit margin improved to 44.2% for the second quarter, compared to 43.6% in the prior year, reflecting favorable pricing and productivity impacts, despite inflationary pressures. Operating income also saw a notable increase, with $265.8 million reported for the second quarter, up from $219.7 million in the same quarter last year. For the first half, operating income rose to $511.8 million from $405.2 million, attributed to increased sales volume and pricing, partially offset by inflation and tariff costs.

In terms of strategic developments, STERIS completed a tuck-in acquisition for approximately $15 million during the first half of fiscal 2026, aimed at expanding its product and service offerings in the Healthcare segment. The company also continued to benefit from the divestiture of its Dental segment, which was sold for $787.5 million in May 2024, allowing for a focus on core operations. The restructuring plan initiated in May 2024, which included the elimination of approximately 300 positions, is expected to enhance profitability and improve operational efficiency.

Operationally, STERIS reported a total of 98.1 million ordinary shares outstanding as of September 30, 2025. The company’s cash and cash equivalents increased to $319.2 million from $171.7 million at the end of the previous fiscal year. Cash flows from operations for the first half of fiscal 2026 were $707.8 million, compared to $554.5 million in the same period last year, with free cash flow also rising to $527.7 million from $344.5 million. The company’s debt-to-total capital ratio improved to 21.3% from 23.6% at the end of the previous fiscal year, reflecting a stronger balance sheet.

Looking ahead, STERIS remains optimistic about its growth trajectory, driven by increasing demand for healthcare services and products, particularly in light of an aging global population. The company anticipates continued revenue growth across its segments, supported by strategic acquisitions and operational efficiencies. However, it also acknowledges potential challenges from inflationary pressures and market conditions that could impact future performance.